TRVN: Trevena Total Debt to Capital
Trevena, Inc. (TRVN) is currently in a lull due to low demand for the drug Olinvyk, forcing management to implement strict cost-cutting measures. This price chart reflects a debt-to-equity ratio of 0.00. The company develops unique CNS treatments using the biased ligand method to combat pain without the risk of addiction. However, leadership at this micro-cap biotech is facing a capital shortage and regulatory challenges.
%20-%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_TRVN_-_Trevena-Inc._-_Debt-to-Capital "Total Debt to Equity Ratio: Trevena, Inc. (TRVN) for 07/04/2022 - 10/19/2024 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Trevena Inc (TRVN)
- price and consensus price forecast:
- market capitalization information:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Trevena, Inc.|TRVN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Trevena, Inc.|TRVN - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Trevena|TRVN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Trevena|Quick Liquidity Indicator trevena.com
- earnings and market ratios statistics:
Fundamental valuation:TRVN, Trevena
The virtual model of Trevena, Inc. (TRVN), which delegates trials to external CROs, minimizes capital expenditures, directly impacting the balance sheet structure. By analyzing changes in the debt-to-equity ratio, investors assess the proportion of total liabilities relative to shareholders' equity: a decrease in this ratio confirms crisis resilience, whereas an increase signals heightened debt leverage and credit risks.
Competitor analysis for Trevena, Inc.
Debt to Equity Biogen|Debt to Equity Ratio NBIX (Neurocrine)|Total Debt to Capital RGC|AXSM - Debt to Capital|ACADIA Pharmaceuticals - Total Debt to Equity Ratio|Total Debt to Capital xenon-pharma.com XENE|VKTX - Debt to Equity|All Debt to Shareholders' Equity Ratio SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Debt to Equity|Debt to Capital Denali Corp (DNLI)|Total Debt to Equity Ratio HRMY|BHVN (biohavenpharma.com) - Aggregate Debt to Capital|Debt to Equity Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital PRAX (Praxis Medicines)|Anavex Life Sciences Corp (AVXL) - Debt to Capital|CBLL: Total Debt to Equity Ratio|PRTA: Debt to Equity|ALEC: Total Debt to Capital|Debt to Capital Annexon Biosciences (ANNX)|Debt to Equity Omeros Corp|Debt to Equity Ratio NGNE (Neurogene Therapeutics)|Total Debt to Capital ACIU|Total Debt to Capital voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio SCLX|Tevogen Bio Holdings, Inc. - Total Debt to Capital|Total Debt to Capital Coefficient Alpha Cognition ACOG|Cognition Therapeutics (CGTX) - Debt to Equity|Debt to Equity Ratio IKT|SAVA (Cassava Sciences) - Total Debt to Capital|Total Debt to Equity Ratio Assertio Therapeutics (ASRT)|Total Debt to Equity Ratio COYA (Coya Therapeutics, Inc.)|Total Debt to Capital Coefficient vistagen.com|Ovid Therapeutics - Total Debt to Equity Ratio|Aggregate Debt to Capital ABOS (acumenpharm.com)|CRVO - Debt to Equity|All Debt to Shareholders' Equity Ratio ATHE (Alterity Therapeutics)|CLNN (clene.com) - Total Debt to Equity Ratio|PEPG (PepGen) - Debt to Equity|Debt to Equity Jupiter Neurosciences Inc|Debt to Equity Ratio RLMD (relmada.com)|Debt to Equity Annovis Bio (ANVS)|gracetx.com - Debt to Equity Ratio|Total Debt to Capital AIFF (Firefly Neuroscience Inc)|ANEW Medical (KLTO) - Debt to Capital|NRSN: Total Debt to Equity Ratio|RVPH - Total Debt to Capital|metaviatx.com (MTVA) - Debt to Equity|NeurAxis Inc. - All Debt to Shareholders' Equity Ratio|Debt to Equity Helius Medical Technologies, Inc.|Debt to Capital Passage Bio Corp PASG|Total Debt to Equity Ratio NEUP (Neuphoria Therapeutics Inc.)|Aggregate Debt to Capital NERV|Debt to Equity Athira Pharma ATHA|All Debt to Shareholders' Equity Ratio ADXN|Alzamend - Total Debt to Capital|Debt to Capital Cyclerion Therapeutics|PTIX (protagenic.com) - Total Debt to Equity Ratio|KTTA (Pasithea Therapeutics Corp.) - Debt to Equity|CRGT (Cortigent Inc) - Total Debt to Capital|Debt to Capital Avenue Therapeutics Inc. ATXI|Debt to Equity Brainstorm Cell Therapeutics, Inc. (BCLI)|Cara Therapeutics Inc - Debt to Equity Ratio|Total Debt to Capital CHRO (Chromocell Therapeutics)|Total Debt to Capital Eliem Therapeutics, Inc. ELYM|ITCI: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio LBPH (Longboard Pharmaceuticals Inc)|MRNS: Total Debt to Capital|NKGN - Total Debt to Capital Coefficient|Debt to Equity NeuroBo Pharmaceuticals|Debt to Equity Ratio SAGE (sagerx.com)|Total Debt to Capital SNPX|Total Debt to Equity Ratio vigilneuro.com VIGL|Anew Medical - Total Debt to Equity Ratio|Total Debt to Capital Coefficient Cerevel Corp (CERE)